Skip to content

Released Mar 5, 2024, after the close

10-K filed Mar 5, 2024, 65 days after period end · 0000950170-24-025877

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$200.42Mderived+64.0% vs Q4 2022+8.9% vs Q3 2023
Net Income-$22.17MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$136,630,000+53.2%
Operating Incomederived-$18,315,000N/M
Operating Cash Flowderived-$6,694,000N/M
Free Cash Flowderived-$21,255,000N/M
Margins · derived
Gross margin68.2%−4.8 pt vs Q4 2022
Operating margin-9.1%−0.1 pt vs Q4 2022
Net margin-11.1%−5.3 pt vs Q4 2022

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Revenue$200.42M$122.23M$125.06M$117.62M
Net Income-$22.17M-$7.06M-$32.81M-$9.38M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR